Evidence map›Paper›PMID 38693739›Full record

ReviewEndocrine, metabolic & immune disorders drug targets2025

Beneficial Effects of PIN1 Inhibition on Diabetes Mellitus: A Concise Review.

Meeramol C Chellappan, Soumya Vasu, Shriraam Mahadevan, Muthu Kumaradoss Kathiravan, Saravanan Jayaraman, Soniya Naik

Abstract readReview
PubMed Publisher
In one paragraph

Review in Endocrine, metabolic & immune disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Meeramol C ChellappanDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, (DU) Porur-600 116, Chennai, India.
Soumya VasuDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, (DU) Porur-600 116, Chennai, India.
Shriraam MahadevanDepartment of Endocrinology, Sri Ramachandra Institute of Higher Education and Research, (DU) Porur-600 116, Chennai, India.
Muthu Kumaradoss KathiravanDepartment of Pharmaceutical Chemistry, SRM College of Pharmacy, Kattankulathur, Chennai, India.
Saravanan JayaramanDepartment of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, 643001, India.
Soniya NaikDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, (DU) Porur-600 116, Chennai, India.
Sri Ramachandra Institute of Higher Education and Research · INJSS Academy of Higher Education and Research · INSRM Institute of Science and Technology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus is a long-term medical illness in which the body either becomes resistant to insulin or fails to produce it sufficiently. Mostly, combinatorial therapy is required to control blood glucose levels. However, combinatorial therapy has detrimental side effects. The prevalence of the cases and subsequent increases in medical costs of the same intimidate human health globally. While there have been a lot of studies focused on developing diabetic regimens that work to lower blood glucose levels, their effectiveness is short-lived because of unfavorable side effects, such as weight gain and hypoglycemia. In recent years, the PIN1 (protein interacting with NIMA) enzyme has attracted the attention of researchers. Previous studies suggested that PIN1 may act on the various substrates that are involved in the progression of T2DM and also help in the management of diabetes-related disorders. Thus, the focus of the current review is to examine the correlation between PIN1, T2DM and its related disorders and explore the possibility of developing novel therapeutic targets through PIN1 inhibition.

Indexed as

Diabetes Mellitus, Type 2Enzyme InhibitorsHypoglycemic AgentsNIMA-Interacting Peptidylprolyl IsomeraseAnimalsBlood GlucoseHumansBlood GlucoseEnzyme InhibitorsHypoglycemic AgentsNIMA-Interacting Peptidylprolyl IsomerasePIN1 protein, humandiabetesdiabetes mellitushypoglycemia.PIN1therapeutic targetType 2 DM

Identifiers

PMID38693739
OpenAlexW4396591116

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.